Together with the upregulated PD-L1 expression on pHNSCC cells after co-culture with anti-HER1 CAR-NK-92 cells, this suggests CAR-based approaches targeting a single tumor-associated antigen may not be suitable for monotherapy, and hence, may not be able to prevent high relapse rates and treatment resistance. The gene discussed is EGFR; the disease is neoplasm.